MD4081G2 - Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică - Google Patents

Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică Download PDF

Info

Publication number
MD4081G2
MD4081G2 MDA20070265A MD20070265A MD4081G2 MD 4081 G2 MD4081 G2 MD 4081G2 MD A20070265 A MDA20070265 A MD A20070265A MD 20070265 A MD20070265 A MD 20070265A MD 4081 G2 MD4081 G2 MD 4081G2
Authority
MD
Moldova
Prior art keywords
rifaximin
polymorphous
forms
processes
polymorphous forms
Prior art date
Application number
MDA20070265A
Other languages
English (en)
Russian (ru)
Other versions
MD4081F2 (ro
MD20070265A (ro
Inventor
Джузеппе Клавдио ВИСКОМИ
Мануэла Кампана
Донателла Конфортини
Мария Мириам Барбанти
Дарио Брага
Original Assignee
Alfa Wassermann S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34934045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4081(G2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann S.P.A. filed Critical Alfa Wassermann S.P.A.
Publication of MD20070265A publication Critical patent/MD20070265A/ro
Publication of MD4081F2 publication Critical patent/MD4081F2/ro
Publication of MD4081G2 publication Critical patent/MD4081G2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
    • C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
    • C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Invenţia se referă la formele polimorfe de rifaximină, şi anume la formele δ şi ε.Forma polimorfă de rifaximină δ este caracterizată printr-un conţinut de apă de la 2,5% până la 6,0%, de preferinţă de la 3,0% până la 4,5%, şi o difractogramă pe pulbere cu raze X având vârfuri la valorile unghiurilor de difracţie 2Θ 5,7°±0,2, 6,7°±0,2, 7,1°±0,2, 8,0°±0,2, 8,7°±0,2, 10,4°±0,2, 10,8°±0,2, 11,3°±0,2, 12,1°±0,2, 17,0°±0,2, 17,3°±0,2, 17,5°±0,2, 18,5°±0,2, 18,8°±0,2, 19,1°±0,2, 21,0°±0,2, 21,5°±0,2.Forma polimorfă de rifaximină ε este caracterizată printr-o difractogramă pe pulbere cu raze X având vârfuri la valorile unghiurilor de difracţie 2Θ 7,0°±0,2, 7,3°±0,2, 8,2°±0,2, 8,7°±0,2, 10,3°±0,2, 11,1°±0,2, 11,7°±0,2, 12,4°±0,2, 14,5°±0,2, 16,3°±0,2, 17,2°±0,2, 18,0°±0,2, 19,4°±0,2.Invenţia se referă de asemenea la procedee de obţinere a formelor polimorfe de rifaximină δ şi ε printr-un proces de cristalizare desfăşurat prin diluarea rifaximinei brute în alcool etilic şi precipitarea prin adăugarea apei la o anumită temperatură şi într-o perioadă prestabilită de timp cu uscarea ulterioară în condiţii de vid sau la o presiune atmosferică normală până la atingerea unui conţinut anumit de apă în produsul finit.Formele polimorfe de rifaximină obţinute pot fi utilizate în calitate de preparate medicamentoase cu acţiune antibiotică pentru administrare orală şi topică.
MDA20070265A 2005-03-03 2006-02-27 Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică MD4081G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05004695.2A EP1698630B1 (en) 2005-03-03 2005-03-03 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
PCT/EP2006/001755 WO2006094662A1 (en) 2005-03-03 2006-02-27 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal

Publications (3)

Publication Number Publication Date
MD20070265A MD20070265A (ro) 2008-05-31
MD4081F2 MD4081F2 (ro) 2010-12-31
MD4081G2 true MD4081G2 (ro) 2011-07-31

Family

ID=34934045

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20070265A MD4081G2 (ro) 2005-03-03 2006-02-27 Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică

Country Status (27)

Country Link
US (9) US8193196B2 (ro)
EP (1) EP1698630B1 (ro)
JP (2) JP5737825B2 (ro)
KR (1) KR100885755B1 (ro)
CN (1) CN1900077B (ro)
AU (1) AU2006222312B8 (ro)
BR (1) BRPI0608073A8 (ro)
CA (1) CA2594789C (ro)
DK (1) DK1698630T3 (ro)
ES (1) ES2522895T3 (ro)
HR (1) HRP20070433B1 (ro)
IL (1) IL184694A0 (ro)
MA (1) MA29345B1 (ro)
MD (1) MD4081G2 (ro)
ME (1) ME00272B (ro)
MX (1) MX2007010742A (ro)
NO (1) NO342197B1 (ro)
NZ (1) NZ556737A (ro)
PL (1) PL1698630T3 (ro)
PT (1) PT1698630E (ro)
RS (1) RS54570B1 (ro)
RU (1) RU2397985C2 (ro)
SI (1) SI1698630T1 (ro)
TN (1) TNSN07292A1 (ro)
UA (1) UA89809C2 (ro)
WO (1) WO2006094662A1 (ro)
ZA (1) ZA200707397B (ro)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009108730A2 (en) 2008-02-25 2009-09-03 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
ES2727728T3 (es) 2008-02-26 2019-10-18 Salix Pharmaceuticals Ltd Métodos para el tratamiento del síndrome del intestino irritable
PL2294012T3 (pl) 2008-05-07 2014-12-31 Salix Pharmaceuticals Inc Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit
DK2327407T3 (da) 2008-09-26 2014-08-25 Aska Pharm Co Ltd Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
SMT202400116T1 (it) * 2008-10-02 2024-05-14 Salix Pharmaceuticals Ltd Trattamento dell’encefalopatia epatica utilizzando rifaximina
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
WO2011032085A1 (en) 2009-09-13 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ，リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN101836959A (zh) * 2010-05-20 2010-09-22 山东达因海洋生物制药股份有限公司 一种制备几乎无苦味利福昔明干混悬剂的方法
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
HUE049986T2 (hu) 2010-07-12 2020-11-30 Salix Pharmaceuticals Inc Rifaximin készítmények és ezek alkalmazásai
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
AU2014252219B2 (en) 2013-04-12 2018-11-22 Alfasigma S.P.A. NSAID administration and related compositions, methods and systems.
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US20150103715A1 (en) * 2013-10-14 2015-04-16 Qualcomm Incorporated Downlink control format indicator
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
MX375805B (es) 2014-05-04 2025-03-07 Salix Pharmaceuticals Inc Microbiota ibs y sus usos.
PT3546464T (pt) 2014-05-12 2020-08-05 Alfasigma Spa Preparação e utilização da forma cristalina tau de rifaximina solvatada com degme
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
TR201909029T4 (tr) 2016-03-24 2019-07-22 Sandoz Ag Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler.
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
PL3518924T3 (pl) 2016-09-30 2023-01-09 Salix Pharmaceuticals, Inc. Postacie stałej dyspersji ryfaksyminy
PL3416627T3 (pl) 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine
HUE054832T2 (hu) 2017-06-26 2021-10-28 Biofer Spa Pirido-imidazo rifamicinszármazékok baktériumellenes szerként
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
AU2020355603B2 (en) 2019-09-24 2026-02-12 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
CN116018133A (zh) 2020-06-26 2023-04-25 博士医疗爱尔兰有限公司 靶向释放利福昔明组合物
CN117567449A (zh) * 2020-10-13 2024-02-20 勃林格殷格翰国际有限公司 再加工方法
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341785A (en) * 1980-05-22 1982-07-27 Alfa Farmaceutici S.P.A. Imidazo-rifamycin derivatives with antibacterial utility
EP0161534A2 (en) * 1984-05-15 1985-11-21 ALFA FARMACEUTICI S.p.A. New process for the synthesis of pyrido-imidazo-refamycins
WO2006094662A1 (en) * 2005-03-03 2006-09-14 Alfa Wassermann S.P.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal
MD3653F2 (ro) * 2003-11-07 2008-07-31 Alfa Wassermann S.P.A. Forme polimorfe de rifaximina, procedee deobtinere a lor si utilizarea acestora in calitatede antibiotic

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751182A (fr) 1969-05-30 1970-11-03 Takeda Chemical Industries Ltd Procede de fabrication d'antibiotiques
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
KR0170000B1 (ko) * 1990-06-29 1999-02-01 레나토 스가르비 순수한 결정 형태의 리파펜틴
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6271001B1 (en) 1995-03-23 2001-08-07 Bio Polymers Pty. Ltd. Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
EP0935417B1 (en) 1996-10-16 2009-05-06 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU1234002A (en) * 2000-10-31 2002-05-15 Ciba Sc Holding Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
TR200402446T4 (tr) 2001-05-03 2004-12-21 Farmigea S.P.A. Servik aşınmanın tedavisi için sükralfatın kullanımı.
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003101460A1 (en) 2002-06-03 2003-12-11 Cac Corporation External preparations for treating dermatitis
RU2223764C1 (ru) * 2002-07-16 2004-02-20 Закрытое акционерное общество "АИП-Наука" Способ получения липосомальной формы рифампицина
CZ13908U1 (cs) 2003-10-08 2004-01-05 Cpn Spol. S R.O. Kosmetický přípravek s vysokomolekulární antioxidační složkou
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
AU2005263958B2 (en) 2004-07-16 2011-04-14 Cipla Limited Anti-histaminic composition
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP2420226B1 (en) 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
JP2010259452A (ja) * 2007-08-21 2010-11-18 Konica Minolta Medical & Graphic Inc 画像診断支援装置及び画像診断支援方法
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2009108730A2 (en) 2008-02-25 2009-09-03 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
ES2727728T3 (es) 2008-02-26 2019-10-18 Salix Pharmaceuticals Ltd Métodos para el tratamiento del síndrome del intestino irritable
PL2294012T3 (pl) 2008-05-07 2014-12-31 Salix Pharmaceuticals Inc Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
SMT202400116T1 (it) 2008-10-02 2024-05-14 Salix Pharmaceuticals Ltd Trattamento dell’encefalopatia epatica utilizzando rifaximina
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
JP5276505B2 (ja) * 2009-04-06 2013-08-28 株式会社ユニバーサルエンターテインメント 遊技機
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
WO2010148040A1 (en) 2009-06-15 2010-12-23 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
WO2011032085A1 (en) 2009-09-13 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
WO2011051971A2 (en) 2009-10-27 2011-05-05 Lupin Limited Solid dispersion of rifaximin
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US20130202654A1 (en) 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ，リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EP2544660B1 (en) 2010-03-10 2018-06-13 Lupin Limited Rifaximin ready-to-use suspension
ES2682051T3 (es) 2010-04-23 2018-09-18 The Procter & Gamble Company Composición detergente
CA2800668A1 (en) 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
EP2582707A4 (en) 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
HUE049986T2 (hu) 2010-07-12 2020-11-30 Salix Pharmaceuticals Inc Rifaximin készítmények és ezek alkalmazásai
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
AU2013212008A1 (en) 2012-01-25 2014-07-10 Alfa Wassermann S.P.A. Rifaximin derivative and uses thereof
JP2013184902A (ja) 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
AU2014252219B2 (en) 2013-04-12 2018-11-22 Alfasigma S.P.A. NSAID administration and related compositions, methods and systems.
CA2912712A1 (en) 2013-05-17 2014-11-20 Salix Pharmaceuticals, Inc. Methods of using rifaximin in position emission tomography (pet) scans
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
PT3546464T (pt) 2014-05-12 2020-08-05 Alfasigma Spa Preparação e utilização da forma cristalina tau de rifaximina solvatada com degme
WO2016063289A2 (en) 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
WO2017021975A1 (en) 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
TR201909029T4 (tr) 2016-03-24 2019-07-22 Sandoz Ag Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler.
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (en) 2017-03-02 2018-09-07 Granules India Limited Rifaximin crystalline form
WO2018178777A1 (en) 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
PL3416627T3 (pl) 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
HUE054832T2 (hu) 2017-06-26 2021-10-28 Biofer Spa Pirido-imidazo rifamicinszármazékok baktériumellenes szerként

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341785A (en) * 1980-05-22 1982-07-27 Alfa Farmaceutici S.P.A. Imidazo-rifamycin derivatives with antibacterial utility
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
EP0161534A2 (en) * 1984-05-15 1985-11-21 ALFA FARMACEUTICI S.p.A. New process for the synthesis of pyrido-imidazo-refamycins
EP0161534B1 (en) * 1984-05-15 1989-09-20 ALFA FARMACEUTICI S.p.A. New process for the synthesis of pyrido-imidazo-refamycins
MD3653F2 (ro) * 2003-11-07 2008-07-31 Alfa Wassermann S.P.A. Forme polimorfe de rifaximina, procedee deobtinere a lor si utilizarea acestora in calitatede antibiotic
WO2006094662A1 (en) * 2005-03-03 2006-09-14 Alfa Wassermann S.P.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal

Also Published As

Publication number Publication date
BRPI0608073A2 (pt) 2009-11-03
US8741904B2 (en) 2014-06-03
HRP20070433A2 (en) 2007-11-30
US9271968B2 (en) 2016-03-01
WO2006094662A1 (en) 2006-09-14
CA2594789C (en) 2010-09-14
DK1698630T3 (da) 2014-12-08
JP2008531623A (ja) 2008-08-14
MD4081F2 (ro) 2010-12-31
NZ556737A (en) 2011-11-25
US20200277301A1 (en) 2020-09-03
US8518949B2 (en) 2013-08-27
KR100885755B1 (ko) 2009-02-26
US20120245355A1 (en) 2012-09-27
RU2007136430A (ru) 2009-04-10
CN1900077A (zh) 2007-01-24
ES2522895T3 (es) 2014-11-19
NO20074988L (no) 2007-11-30
US8193196B2 (en) 2012-06-05
HK1096396A1 (en) 2007-06-01
TNSN07292A1 (en) 2008-12-31
RS54570B1 (sr) 2016-06-30
CN1900077B (zh) 2012-04-11
RS20070364A (sr) 2009-01-22
PT1698630E (pt) 2014-09-15
US20180291032A1 (en) 2018-10-11
SI1698630T1 (sl) 2015-01-30
PL1698630T3 (pl) 2014-12-31
HRP20070433B1 (hr) 2015-02-27
AU2006222312A1 (en) 2006-09-14
US20200002350A1 (en) 2020-01-02
NO342197B1 (no) 2018-04-16
CA2594789A1 (en) 2006-09-14
EP1698630A8 (en) 2006-10-25
EP1698630B1 (en) 2014-09-03
EP1698630A1 (en) 2006-09-06
US20220119403A1 (en) 2022-04-21
MX2007010742A (es) 2007-09-12
JP2013216710A (ja) 2013-10-24
AU2006222312B8 (en) 2011-11-17
MEP34408A (en) 2011-02-10
AU2006222312B2 (en) 2011-11-03
UA89809C2 (uk) 2010-03-10
KR20060096242A (ko) 2006-09-11
BRPI0608073A8 (pt) 2017-12-26
MA29345B1 (fr) 2008-03-03
US10703763B2 (en) 2020-07-07
US20090130201A1 (en) 2009-05-21
US20150073007A1 (en) 2015-03-12
ZA200707397B (en) 2009-03-25
MD20070265A (ro) 2008-05-31
JP5737825B2 (ja) 2015-06-17
US20130310410A1 (en) 2013-11-21
ME00272B (me) 2011-05-10
RU2397985C2 (ru) 2010-08-27
IL184694A0 (en) 2007-12-03
US20160362419A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
MD4081F2 (ro) Forme polimorfe de rifaximina, procedee de obtinere si utilizare a acestora in calitate de preparate medicamentoase cu activitate antibiotica
MD3653G8 (ro) Forme polimorfe de rifaximină, procedee de obţinere a lor şi utilizarea acestora în calitate de antibiotic
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2008123373A1 (ja) コロイダルシリカ及びその製造方法
HUP0202609A2 (hu) Rapamicinszármazékok regioszelektív előállítása
WO2008020421A3 (en) Compositions comprising calcium citrate malate and methods for making the same
JP5462996B2 (ja) 垂盆草から得られる肝保護剤、該肝保護剤を含有する医薬又は食品、及び垂盆草から得られる新規メガスチグマン化合物。
WO2004096149A3 (en) Industrially scalable nucleoside synthesis
WO2005063731A3 (en) Production of dihydronepetalactone by reduction of nepetalic acid
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2008067156A3 (en) Production of high-purity titanium monoxide and capacitor production therefrom
SG151297A1 (en) Process for producing flavone c glycoside derivatives
EP3178833B1 (en) Crystal of alkali metal n-acetylneuraminate anhydrate, and method for producing same
CN109913953B (zh) 戊二胺制备过程中含硫酸钙固渣的处理方法
WO2006135656A3 (en) Processes for the preparation of paclitaxel
WO2006110534A3 (en) A process for preparing a crystalline form of halobetasol propionate
CN109928771A (zh) 一种中低温日用镁质瓷的制备方法
CN109928725A (zh) 一种高温日用细瓷的制备方法
WO2006023669A3 (en) Process for the production of levorphanol and related compounds
CN109928719A (zh) 一种低温日用陶瓷的制备方法
GB2441902A (en) Novel method for preparing ginseng to obtain increased amount of ginsenoside RG5
Dong et al. STUDIES ON SYNTHESIS OF BETA-SiAlON AND BETA-SiAlON-SiC COMPOSITES
Zhang et al. Synthesis of O'-sialon powder by reduction-nitridation method.
Zhang Synthesis of AlON powder by sol-gel and reduction-nitridation method.
CN109160734A (zh) 树皮釉及其制备方法

Legal Events

Date Code Title Description
FG4A Patent for invention issued
TC4A Change of name of proprietor (patent for invention)

Owner name: ALFASIGMA S.P.A., IT VIALE SARCA N. 223, MILANO (M

Free format text: PREVIOUS NAME OF PROPRIETOR: ALFA WASSERMANN S.P.A., IT VIA ENRICO FERMI, 1, I-65020 ALANNO (PE), ITALIA